BioSpace News Archive

On October 8 and 9, the National Organization for Rare Disorders (NORD®) virtually hosted the 2020 Rare Diseases and Orphan Products Breakthrough Summit, the first time the organization representing over 25 million Americans impacted by rare diseases has presented the conference exclusively online

A new era of healthcare was ushered in today as Atrium Health and Wake Forest Baptist Health, including Wake Forest School of Medicine, officially joined together as a single enterprise, Atrium Health.

Amwell®, (NYSE: AMWL) (the “Company”) a national telehealth leader, today announced the appointment of Ms. Deborah C. Jackson to the Company’s Board of Directors, effective immediately.

Axon Therapies, a Coridea portfolio company focused on addressing one of the root causes of heart failure, today announced positive interim results from their first-in-human (FIH) trial of splanchnic ablation for volume management, or SAVM, using the Satera™ Ablation System.

Leaders in many top organizations and institutions have played a major role in using computational intelligence and pushing the boundaries of how the Wolfram technology stack is leveraged for innovation across fields and disciplines.

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming data presentations at ASN’s Kidney Week 2020 Reimagined from October 22-25, 2020.

The University of Tokyo and Eisai Co., Ltd. announced today a collaboration aiming for the development and drug discovery of targeted protein degradation technology has been created, with the establishment of a social cooperation program, “Protein Degradation Drug Discovery”.

The Parkinson Foundation of the National Capital Area (PFNCA) will host its annual awareness and fundraising walk – Walk Off Parkinson’s – virtually on Oct. 14 and Oct. 20 , 2020. The program, which starts at 6:30 p.m. ET each day, features educational and inspirational content from 18 doctors who are Movement Disorder Specialists

Platform measures changes in H3K4me3 histone modifications to predict optimal growth factors required to both maintain cells in culture and support conversion between cell types EpiMOGRIFY co-developed and co-owned by Duke-NUS, Monash University and Mogrify Company’s platforms support the development of scalable off-the-shelf cell therapies for diseases with a

careMESH today announced that Gustavo Bonany has been appointed as chief technology officer (CTO).